CompoAtlas

Body Rejuvenation - Prolax

Originaltext auf Französisch.

In Kanada zugelassenes natürliches Gesundheitsprodukt

Falls dieses Produkt in Frankreich verkauft würde

Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut QuelleTäglich höchstens, Erwachsene
Bifidobacterium breve

Quelle : UB8674

0,33 Milliards d'UFCNicht berechnet
Bifidobacterium breve

Quelle : Bifidobacterium breve - Cellule entière

0,33 Milliards d'UFCNicht berechnet
Plantago ovata

Quelle : Enveloppe

2.128 mgNicht berechnet
Bifidobacterium longum subsp. infantis

Quelle : Bifidobacterium longum subsp. Infantis - Whole Cell

0,33 Milliards d'UFCNicht berechnet
Bifidobacterium longum subsp. infantis

Quelle : UB9214

0,33 Milliards d'UFCNicht berechnet
Enzymes pancréatiques

Quelle : Sus scrofa - pancréas

Stärke : 34.450 Unité d'activité protéase de la USP Protease

325 mgNicht berechnet
Enzymes pancréatiques

Quelle : Sus scrofa - pancréas

Stärke : 7.832,5 Unité d'activité lipase de la USP Triacylglycerol lipase

Nicht angegebenNicht berechnet
Enzymes pancréatiques

Quelle : Sus scrofa - pancréas

Stärke : 37.350 unité d¿activité amylase de la USP alpha-Amylase

Nicht angegebenNicht berechnet
Lacticaseibacillus casei

Quelle : UB1499

7,7473 Milliards d'UFCNicht berechnet
Chondrus crispus

Quelle : En entier

210 mgNicht berechnet
Capsicum annuum

Quelle : Capsicum annuum - fruit

20 mgNicht berechnet
Chondrus crispus20 mgNicht berechnet
Frangula purshiana

Quelle : Frangula purshiana - Écorce âgée

180 mgNicht berechnet
Juglans cinerea160 mgNicht berechnet
Rheum officinale

Quelle : Rheum officinale - Racine et rhizome

110 mgNicht berechnet
Zingiber officinale

Quelle : Zingiber officinale - Rhizome

20 mgNicht berechnet
Syzygium aromaticum53 mgNicht berechnet
Lacticaseibacillus rhamnosus

Quelle : UB5115

7,7473 Milliards d'UFCNicht berechnet
Lactiplantibacillus plantarum

Quelle : Lactiplantibacillus Plantarum - Cellule entière

0,077 Milliards d'UFCNicht berechnet
Lactiplantibacillus plantarum

Quelle : UB2783

0,077 Milliards d'UFCNicht berechnet
Lacticaseibacillus paracasei

Quelle : UB1978

0,055 Milliards d'UFCNicht berechnet
Vitamine C

Quelle : Acide ascorbique

6 mgNicht berechnet
Morella cerifera

Quelle : Écorce de racine

70 mgNicht berechnet
Hibiscus sabdariffa

Quelle : Fleur

126 mgNicht berechnet

Nicht arzneiliche Inhaltsstoffe

Hypromellose, acide oléique, Trehalose, Feuille de stevia rebaudiana, Fécule de pommes de terre, Alginate de sodium, Phosphate dicalcique, Dioxyde de silice, Acide stéarique, Eau d'ammoniaque, Triglycérides à chaîne moyenne, Stéarate de magnésium, Eau purifiée, Extrait de soie de maïs, Croscarmellose de sodium, Xylooligosaccharides, Ethylcellulose

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
Adultesminimum : 19 ansNon préciséeNon précisée

In Kanada zugelassene Verwendungen

Acidophilus Ultra DAILY CARE III: Source of probiotics. Acidophilus Ultra DAILY CARE III: Helps support intestinal/gastrointestinal health. Acidophilus Ultra DAILY CARE III: Could promote a favorable gut flora. Prolax: Cascara sagrada is traditionally used in herbal medicine as a stimulant laxative for short term relief of occasional constipation. Prolax: Used in herbal medicine to promote bowel movement by direct action on the large intestine. Ultra Fibre Plantago: Psyllium is used in herbal medicine as a bulk-forming laxative and to promote bowel movements by increasing bulk volume and water content. Ultra Fibre Plantago: Psyllium provides gentle relief of constipation and/or irregularity. Rosemary and Clove are Traditionally used in Herbal Medicine as a carminative for the relief of digestive complaints such as flatulence, or abdominal distention. Pancreatin: Digestive aid. Pancreatin: Helps to decrease bloating after high caloric, high fat meals.

Originaltext auf Englisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Cautions and Warnings : Do not follow this program during pregnancy or if you are breastfeeding or have any form of inflammatory bowel disease, such as, Crohn¿s disease, regional ileitis, or ulcerative colitis. Should you experience intense discomfort at any time, discontinue the program immediately. The Body Rejuvenation Kit is a nutritional supplement, not a replacement for proper medical attention. This program is not intended as a treatment for any disease or condition. Consult a licensed health care practitioner of your choice if you need direction on any health care problem. For Prolax: Consult a health care practitioner if symptoms persist or worsen. For Prolax: Consult a health care practitioner prior to use if you are taking cardiac medications such as cardiac glycosides or antiarrhythmic medications, thiazide diuretics, corticosteroids, licorice root or other medications or health products which may aggravate electrolyte imbalance. For Prolax: Consult a health care practitioner prior to use if you have a kidney disorder, faecal impaction or symptoms such as abdominal pain, nausea, vomiting or fever. For Prolax: Reduce dose or stop use if you experience abdominal pain, cramps, spasms and/or diarrhoea. For Prolax: Call a Poison Control Center immediately if overdose or accidental ingestion occurs. For Prolax: Keep out of the reach of children. For Acidophilus: If you have fever, vomiting, bloody diarrhoea or severe abdominal pain, consult a health care practitioner prior to use. For Acidophilus: Stop use and consult a health care practitioner if symptoms of digestive upset (e.g. diarrhea) occur, worsen and/or persists beyond 3 days. For Ultra Fibre Plantago: Consult a health care practitioner if symptoms worsen of if laxative effect does not occur within 7 days. For Ultra Fibre Plantago: Consult a health care practitioner if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking the product. For Ultra Fibre Plantago: Consult a health care practitioner prior to use if you are taking medications which inhibit peristaltic movement (e.g. opoids, loperamide), or if you have symptoms such as abdominal pain, nausea, vomiting or fever (as these could be signs of abnormal constrictions of the gastrointestinal tract, disease of the esophagus and/or the superior opening of the stomach (cardia), potential or existing intestinal blockage, paralysis of the intestine, megacolon, faecal impaction, inflamed bowel or appendicitis). For Ultra Fibre Plantago: Do not exceed the recommended dosage. For Ultra Fibre Plantago: Consult a health care practitioner prior to use if liver function is impaired or if taking acetaminophen or anticoagulants. For Ultra Fibre Plantago: Not for prolonged use in high doses except under supervision of a qualified health care practitioner. For Ultra Fibre Plantago: Consult a health care practitioner prior to use if you have stomach ulcers or inflammation. For Springlife: Stop use and seek medical attention immediately if you experience dizziness, confusion, muscle weakness or pain, abnormal heartbeat and/or difficulty breathing. For Springlife: If you have profuse mucous, consult a health care practitioner prior to use. For Pancreatin: Consult a health care practitioner if symptoms persist or worsen. For Pancreatin: Consult a health care practitioner prior to use if you are pregnant or breastfeeding. For Pancreatin: Consult a health care practitioner prior to use if you have diabetes, pancreatitis, pancreatic exocrine insufficiency or cystic fibrosis. For Pancreatin: Storage conditions: Store in a tightly closed, light-resistant container in a cool, dry place.

Originaltext auf Englisch.

Contra-Indications : For Prolax: Do not use this product if you are pregnant or breastfeeding. For Prolax: Do not use this product if you have abnormal constrictions of the gastrointestinal tract, potential or existing intestinal blockage, atonic bowel, appendicitis, inflammatory colon disease such as Crohn's disease or ulcerative colitis, abdominal pain of unknown origin, undiagnosed rectal bleeding, severe dehydration with depleted water or electrolytes or diarrhoea. For Prolax: Do not use if you have hypokalemia, high blood pressure, or a kidney or cardiovascular disorder. For Prolax: Do not use if you have arthritis. For Prolax: Contraindicated in those with a weak stomach and those who do not have constipation. For Acidophilus Ultra: Do not use this product if you have an immune-compromised condition (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment). For Ultra Fibre Plantago: Do not use if you are experiencing a sudden change in bowel habits that has persisted for more than 2 weeks, undiagnosed rectal bleeding, or failure to defaecate following the use of another laxative product. For Ultra Fibre Plantago: Do not use if you have diabetes mellitus in which blood sugars are difficult to regulate. For Ultra Fibre Plantago: Do not use if you have difficulty swallowing. For Ultra Fibre Plantago: Do not use if you are pregnant or breastfeeding or undergoing corticosteroid treatment. For Ultra Fibre Plantago: Do not use if you suffer from febrile disorder. For Ultra Fibre Plantago: Do not use this product if you are taking thiazide diuretics, cardiac glycosides, corticosteroids, stimulate laxatives or other medications which may aggravate electrolyte imbalance. For Ultra Fibre Plantago: Do not use if you have diabetes, high blood pressure, hypokalemia, liver, heart or kidney disorders. For Springlife: Do not take if you are pregnant or breastfeeding. For Springlife: Do not take if you have been diagnosed with a liver disorder or if liver function is impaired; if you are taking acetaminophen or anticoagulants; if you have a fever and/or suffer from a febrile disorder. For Springlife: If you have heart disease, high or low blood pressure, kidney or liver disorder, diabetes or edema (swelling of hands, face and feet) or are taking products containing diuretics, do not use. For Pancreatin: Do not use if you are sensitive to pancreatic enzymes. For Pancreatin: Do not use if you are sensitive to pork proteins.

Originaltext auf Englisch.

Known Adverse Reactions : For Prolax: Stop use if hypersensitivity/allergy occurs. For Prolax: With chronic use or abuse, disturbances of electrolyte balance, especially potassium deficiency, albuminuria and hematuria may occur; Rectal bleeding or failure to have a bowel movement after the use of a laxative may indicate a serious condition. For Prolax: May cause cramp-like discomfort of the gastrointestinal tract, which may require a reduction of dosage. For Prolax: The astringent effect of rhubarb may exacerbate, rather than relieve symptoms of constipation. For Ultra Fibre Plantago: Hypersensitivity, such as allergy, has been known to occur following inhaled and/or ingested psyllium, in which case discontinue use. For Ultra Fibre Plantago: May cause temporary gas and/or bloating. For Ultra Fibre Plantago: Consult a health care practitioner in the event of an allergic reaction, nausea, vomiting, or diarrhea. For Springlife: Large doses (many times the recommended dosage) of bayberry may be emetic and cause stomach problems. For Pancreatin: Nausea, vomiting, abdominal pain/epigastric pain and/or heartburn have been known to occur, in which case discontinue use (and consult a health care practitioner).

Originaltext auf Englisch.

Produktdaten

Andere Namen
Acidophilus Ultra DAILY CARE III
Inhaber
New Roots Herbal Inc.
NPN oder DIN-HM
80115009
Status
Aktive Lizenz
Lizenzdatum
23. Dezember 2021
Überarbeitungsdatum
Nicht angegeben
Form
Kit
Verabreichungsweg
Orale
Art des Antrags
Générale (non traditionelle)

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 80115009

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Offizielle Warnhinweise (Health Canada)

Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:

  • Capsicum annuum
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    CAYENNE - CAPSICUM ANNUUM Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).

    Von Health Canada zitierte Quellen (1)
    • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).

    Von Health Canada zitierte Quellen (2)
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).

    Von Health Canada zitierte Quellen (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Anwendungsbedingung: Digestion; Peripheral circulation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografie von Health Canada vom 27. März 2026

    CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    For external use only (US FDA 2023).

    Von Health Canada zitierte Quellen (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).

    Von Health Canada zitierte Quellen (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).

    Von Health Canada zitierte Quellen (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).

    Von Health Canada zitierte Quellen (1)
    • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Bekannte Nebenwirkungen

    Anwendungsbedingung: All products.

    Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).

    Von Health Canada zitierte Quellen (5)
    • APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
    • Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
    • McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Randomisierte Studie
    • Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Systematische Übersicht

    Monografie von Health Canada vom 27. März 2026

  • Frangula purshiana
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    CASCARA SAGRADA - FRANGULA PURSHIANA

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2020; Brinker 2010; WHO 2002).

    Von Health Canada zitierte Quellen (4)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
    • WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
    • OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2020; Brinker 2010; WHO 2002; Blumenthal et al. 2000).

    Von Health Canada zitierte Quellen (5)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
    • WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
    • OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.

    Gegenanzeigen

    Do not use if you are pregnant or breastfeeding (EMA 2020; Brinker 2010; Blumenthal et al. 2000).

    Von Health Canada zitierte Quellen (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1

    Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2020; Brinker 2010; WHO 2002).

    Von Health Canada zitierte Quellen (4)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
    • WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
    • OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.

    Bekannte Nebenwirkungen

    Stop use if hypersensitivity/allergy or diarrhea occurs (EMA 2020; Brinker 2010).

    Von Health Canada zitierte Quellen (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1

    Monografie von Health Canada vom 30. Mai 2025

  • Zingiber officinale
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    GINGER - ZINGIBER OFFICINALE

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografie von Health Canada vom 19. Dezember 2025

Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.

Das Belegdatum dieser Zutatenliste ist unbekannt.

Das Produkt hat sich geändert? Fotografieren Sie die Verpackung.

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile